<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2006</study_start_year><condition>advanced/recurrent colon cancer or rectal cancer</condition><disease>Advanced/recurrent Colon Cancer Or Rectal Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2616222</full_dataset_link><location>Japan</location><study_start_month>8</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Phase II study of using Carbamazepine for neurosensory toxicity related FOLFOX regimens in patients with advanced/recurrent colorectal cancer (OGSG 0603)</name><description>Interventions: Carbamazepin is administered during FOLFOX therapy. Carbamazepin tablet 100mg, 200mg or granule including Car. 500mg in 1000mg
Primary outcome(s): To test the feasibility of Carmazepin therapy and to evaluate whether Carmazepin has the protective and/or prophylactic effects against peripheral nerve syndrome due to FOLFOX therapy
Study Design: Single arm Non-randomized</description><dates><creation>2006-08-15</creation></dates><accession>2616222</accession><cross_references><Japan Primary Registries Network>JPRN-UMIN000000718</Japan Primary Registries Network></cross_references></HashMap>